Edition:
United Kingdom

Cardinal Health Inc (CAH.N)

CAH.N on New York Stock Exchange

46.67USD
4:48pm BST
Change (% chg)

$0.59 (+1.28%)
Prev Close
$46.08
Open
$46.13
Day's High
$46.80
Day's Low
$45.98
Volume
152,591
Avg. Vol
848,190
52-wk High
$66.42
52-wk Low
$42.18

Latest Key Developments (Source: Significant Developments)

Cardinal Health Inc - Sees Mid-Single Digit Percentage Growth in 2019 Revenue
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Cardinal Health Inc ::CARDINAL HEALTH INC - SEES 2019 REVENUE MID-SINGLE DIGIT PERCENTAGE GROWTH.CARDINAL HEALTH INC - SEES 2019 CAPITAL EXPENDITURES $360M - $390M.CARDINAL HEALTH INC SEES 2019 PHARMACEUTICAL SEGMENT REVENUE WITH MID TO HIGH-SINGLE DIGIT PERCENTAGE GROWTH.CARDINAL HEALTH INC SEES 2019 MEDICAL SEGMENT REVENUE APPROXIMATELY FLAT - PRESENTATION.CARDINAL HEALTH INC SEES 2019 MEDICAL SEGMENT PROFIT WITH MID TO HIGH-SINGLE DIGIT PERCENTAGE GROWTH.CARDINAL HEALTH INC SEES 2019 PHARMACEUTICAL SEGMENT WITH HIGH-SINGLE TO LOW-DOUBLE DIGIT PERCENTAGE DECLINE.  Full Article

Cardinal Health Reports Second Quarter Results For 2019
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Cardinal Health Inc ::CARDINAL HEALTH REPORTS SECOND QUARTER RESULTS FOR FISCAL YEAR 2019.Q2 NON-GAAP EARNINGS PER SHARE $1.29.Q2 GAAP EARNINGS PER SHARE $0.93.Q2 REVENUE $37.7 BILLION VERSUS REFINITIV IBES ESTIMATE OF $36.1 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.09 -- REFINITIV IBES DATA.RAISES FY 2019 NON-GAAP EARNINGS PER SHARE VIEW TO $4.97 TO $5.17.COMPANY RAISES FY19 GUIDANCE.RAISES FY19 GUIDANCE.FY2019 EARNINGS PER SHARE VIEW $5.00 -- REFINITIV IBES DATA.Q2 REVENUE FOR PHARMACEUTICAL SEGMENT INCREASED 8 PERCENT TO $33.7 BILLION.WELL-POSITIONED TO EXCEED OUR COST-SAVINGS TARGETS FOR THE ENTERPRISE.  Full Article

Cardinal Health Recommends Shareholders Reject The Below-Market Mini-Tender Offer By TRC Capital Corporation
Friday, 9 Mar 2018 

March 9 (Reuters) - Cardinal Health Inc ::CARDINAL HEALTH RECOMMENDS SHAREHOLDERS REJECT THE BELOW-MARKET MINI-TENDER OFFER BY TRC CAPITAL CORPORATION.CARDINAL HEALTH - RECEIVED NOTICE OF UNSOLICITED "MINI-TENDER" OFFER BY TRC CAPITAL TO PURCHASE UP TO 2 MILLION OF CO'S COMMON SHARES.CARDINAL HEALTH INC - TRC CAPITAL'S "MINI-TENDER" OFFER IS FOR OFFER PRICE OF $65.85 PER CARDINAL HEALTH SHARE.  Full Article

Cardinal Health Reports Q2 Adj. Earnings Per Share $1.31
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Cardinal Health Inc ::CARDINAL HEALTH REPORTS SECOND-QUARTER RESULTS FOR FISCAL YEAR 2018.Q2 REVENUE $35.2 BILLION.RAISES FY 2018 NON-GAAP EARNINGS PER SHARE VIEW TO $5.25 TO $5.50.Q2 NON-GAAP EARNINGS PER SHARE $1.31 EXCLUDING ITEMS.COMPANY RAISES FY18 OUTLOOK TO REFLECT BENEFITS OF U.S. TAX REFORM.BOARD OF DIRECTORS APPROVES NEW $1 BILLION SHARE REPURCHASE AUTHORIZATION.CARDINAL HEALTH-FOR QUARTER ENDED DEC. 31, 2017, APPLICATION OF LOWER TAX RATE TO FISCAL YEAR-TO-DATE U.S. EARNINGS RESULTED IN A BENEFIT OF $0.20/SHARE.COMPANY IS RAISING ITS OUTLOOK FOR FISCAL 2018 NON-GAAP EPS TO $5.25-$5.50.SECOND-QUARTER REVENUE FOR PHARMACEUTICAL SEGMENT INCREASED 5 PERCENT TO $31.1 BILLION.QTRLY GAAP DILUTED EARNINGS PER SHARE INCREASES 226 PERCENT TO $3.33.AS PART OF U.S. TAX REFORM, CO RECORDED TRANSITIONAL TAX BENEFITS TOTALING $2.83PER SHARE IN QUARTER.EXCLUDING A $0.20 BENEFIT FROM TAX REFORM, QTRLY NON-GAAP EPS IS $1.31.QTRLY NON-GAAP EPS INCREASED 13 PERCENT TO $1.51.Q2 REVENUE VIEW $34.64 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Cordis And Medinol Announce FDA Approval Of EluNIR Drug-Eluting Stent System
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Cardinal Health Inc ::CORDIS AND MEDINOL ANNOUNCE FDA APPROVAL OF THE INNOVATIVE ELUNIR DRUG-ELUTING STENT SYSTEM.  Full Article

Shanghai Pharmaceuticals' unit‍ signs deal to acquire Cardinal in Malaysia
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says its unit‍ Century Global signs deal to acquire Cardinal Malaysia for about $557 million.  Full Article

Cardinal Health says shareholders re-elected all 11 members to board in preliminary voting ​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Cardinal Health Inc :Cardinal Health - ‍based on preliminary results of shareholder voting at co's annual meeting, shareholders re-elected all 11 members to board​.  Full Article

Cardinal Health Inc outlines leadership succession plan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cardinal Health Inc :Cardinal Health Inc outlines leadership succession plan.Cardinal Health Inc - ‍Jorge Gomez, CFO of Cardinal Health's medical segment, to succeed Kaufmann as chief financial officer​.Cardinal Health Inc - ‍Mike Kaufmann named chief executive officer, effective January 1, 2018​.Cardinal Health Inc - ‍George Barrett continues as executive chairman of board through november 2018 annual meeting of shareholders​.Cardinal Health Inc - ‍Kaufmann will succeed George Barrett​.Cardinal Health Inc - ‍Gregory Kenny, Cardinal Health's lead independent director, will assume role of non-executive chairman​.  Full Article

Cardinal Health reports Q1 GAAP earnings per share $0.36
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cardinal Health Inc :Cardinal Health Inc reports first-quarter results for fiscal year 2018.Reaffirms fy 2018 non-GAAP earnings per share view $4.85 to $5.10.Q1 revenue $32.6 billion versus I/B/E/S view $33.48 billion.Q1 GAAP earnings per share $0.36.Q1 earnings per share view $1.00 -- Thomson Reuters I/B/E/S.Cardinal Health Inc - ‍first-quarter revenue for pharmaceutical segment increased 1 percent to $28.9 billion​.Fy2018 earnings per share view $4.95 -- Thomson Reuters I/B/E/S.Cardinal Health Inc - qtrly ‍non-GAAP diluted EPS $1.09​.  Full Article

Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement​
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement​ - SEC filing.Galena Biopharma Inc - ‍pursuant to agreement , co, Cardinal agreed to resolve all of their outstanding disputes over a product swap agreement​.Galena Biopharma Inc - ‍Cardinal will destroy all of zuplenz oral soluble film that is returned as a result of product swap agreement.Galena Biopharma Inc - ‍product swap agreement with Cardinal will be terminated as of effective date of agreement​.  Full Article

After drug distributor charged, Trump sets speech on opioid fight

WASHINGTON, April 24 President Donald Trump is expected to tout his fight against opioid abuse in remarks in Atlanta on Wednesday, a day after his administration brought its first related criminal charges against a major drug distributor and company executives.